Sai Parenterals Ltd

BSE: 544742

66

total announcements

544742.BO · 15 min delayed

BSECompany UpdateResults11 Aug 2026

Sai Parenterals Ltd

Statement on deviation or varition of funds

Sai Parenterals Ltd has submitted a statement on deviation or variation of funds under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has informed that there are no deviations or variations in the utilization of the proceeds of the Initial Public Offer (IPO) during the quarter ended June 30, 2026.

Read more →📎 1 attachment
BSECompany UpdateMgmt Change11 Aug 2026

Sai Parenterals Ltd

Announcement under Regulation 30 (LODR)- Change in Management

Sai Parenterals Ltd announced changes in management, including the re-appointment of Mr. Anil Kumar Karusala as Director and Managing Director, and the resignation of Ms. Shivali Aggarwal as Company Secretary & Compliance Officer. The company also announced the acquisition of a greenfield injectables manufacturing plant and an existing R&D facility, and the ratification of its employee stock option plan.

Read more →📎 1 attachment
BSEResultResults11 Aug 2026

Sai Parenterals Ltd

Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30.06.2026.

Sai Parenterals Ltd announced unaudited financial results for the quarter ended 30.06.2026, along with various board decisions and related party transactions. The company reported a change in the utilization of IPO proceeds, acquisition of a greenfield injectables manufacturing plant, and incorporation of a new step-down subsidiary in the US. The board also re-appointed directors, ratified the ESOP scheme, and approved related party transactions.

Read more →📎 1 attachment
BSEBoard Meeting▲ PositiveResults11 Aug 2026

Sai Parenterals Ltd

Outcome of Board Meeting held on 11th August, 2026 at the registered office of the company.

Sai Parenterals Ltd held a board meeting on August 11, 2026, and approved several items, including un-audited financial results for the quarter ended June 30, 2026, and the re-appointment of directors. The company also announced the acquisition of a greenfield injectables manufacturing plant and the acquisition of an existing R&D facility. Additionally, the company ratified the Sai Parenterals Limited Employee Stock Option Plan, 2025, and the extension of benefits to subsidiary companies.

Read more →📎 1 attachment
← PreviousPage 4 of 4